John Weinberg, MD, COO, Veloxis Pharmaceuticals describes the challenges of organ transplantation. While advancements in the field have minimized the short-term risks of transplantation, the average kidney transplant only lasts about 10-12 years. According to Weinberg, the transience of kidney transplants is often a result of poor compliance with medication and various toxicities such as: tremor, insomnia, diabetes, hypertension and renal dysfunction. Envarsus, which is a new drug in development, is designed to prevent rejection of kidney transplants. Envarsus is a reformulation of the current gold standard medication, tacrolimus, and has been proven to be as effective with half the dosing, in addition to lowering peak concentration